Courage
For Life

SYLVANT^® (siltuximab) Recommended by the National Comprehensive Cancer Network^® (NCCN^®) as the Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) regardless of histopathologic subtype

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT^® (Siltuximab for Injection) in China

EUSA Pharma To Present at the 39th Annual J.P. Morgan Healthcare Conference

EUSA Pharma Announces First Patient Enrolled in a Randomised Phase 3 Clinical Trial Investigating Siltuximab in Hospitalised Patients with COVID-19- or Another Respiratory Virus Infection-Associated Acute Respiratory Distress Syndrome (ARDS)

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA^®▼ (Dinutuximab Beta) in China

EUSA Pharma are proud to be featured in this year’s Sunday Times Sage Tech Track 100

EUSA Pharma are proud to be featured in this year’s Sunday Times Sage Tech Track 100 as one of Britain’s private technology companies with the fastest-growing sales.

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-treated COVID-19 Patients from the SISCO Study

EUSA Pharma and the Papa Giovanni XXIII Hospital, Bergamo, Italy announce initiation of an observational case-control study of siltuximab in patients with COVID-19 who have developed serious respiratory complications

SYLVANT^® (siltuximab) Recommended by the National Comprehensive Cancer Network^® (NCCN^®) Guidelines as a Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) for Patients with Plasmacytic or Mixed Histology